Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $11.0M | $19.7M | $27.4M | $48.1M | $119M | $76.2M | $68.0M | $74.6M | $96.2M |
| Revenue growth | — | — | 79.1% | 38.6% | 75.7% | 147.8% | -36.0% | -10.8% | 9.7% | 28.9% |
| Gross profit | $4.78M | $6.75M | $13.5M | — | — | — | — | $41.3M | $50.1M | $62.1M |
| Gross margin | — | 61.2% | 68.5% | — | — | — | — | 60.7% | 67.1% | 64.6% |
| Operating income | -$4.85M | -$1.06M | $3.66M | -$220K | -$6.24M | -$35.2M | -$5.92M | -$17.2M | -$4.48M | -$16.6M |
| Operating margin | — | -9.6% | 18.5% | -0.8% | -13.0% | -29.5% | -7.8% | -25.3% | -6.0% | -17.3% |
| Net income | -$6.88M | -$2.52M | -$25.0M | -$1.66M | $1.98M | -$8.91M | -$140M | -$68.0M | -$20.2M | -$4.59M |
| Net margin | — | -22.8% | -126.7% | -6.1% | 4.1% | -7.5% | -183.4% | -100.0% | -27.0% | -4.8% |
| EPS (diluted) | -$0.54 | -$0.21 | -$1.56 | -$0.09 | -$0.06 | -$0.23 | -$3.25 | -$1.55 | -$0.44 | -$0.10 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.33M | $605K | $2.35M | $1.21M | $6.64M | -$4.59M | -$8.49M | -$12.5M | $8.43M | $20.1M |
| Capital expenditures | $144K | $144K | $500K | $675K | $1.96M | $8.38M | $10.4M | $6.38M | $3.23M | $9.48M |
| Free cash flow | -$4.47M | $461K | $1.85M | $538K | $4.68M | -$13.0M | -$18.9M | -$18.9M | $5.20M | $10.6M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.41M | $6.66M | $7.03M | $6.45M | $90.4M | $69.9M | $19.4M | $27.9M | $91.5M | $33.0M |
| Total assets | $7.93M | $12.1M | $12.3M | $92.8M | $235M | $554M | $450M | $413M | $399M | $406M |
| Total liabilities | $4.76M | $2.05M | $16.5M | $49.4M | $29.6M | $76.2M | $86.0M | $75.1M | $50.6M | $34.0M |
| Long-term debt | $4.25M | — | — | $13.0K | $655K | $6.35M | $23.8M | $17.6M | $5.00M | $0.00 |
| Shareholders' equity | $3.17M | -$9.53M | $14.6M | $43.3M | $204M | $478M | $364M | $338M | $349M | $372M |
| Retained earnings | -$71.2M | -$74.0M | -$73.1M | $100M | -$97.4M | -$107M | -$247M | -$315M | -$335M | -$340M |
| Shares (wtd avg diluted) | 12.9M | 13.3M | 21.6M | 19.5M | 27.3M | 38.5M | 43.1M | 43.7M | 46.1M | 48.6M |
Every figure is extracted from BIOLIFE SOLUTIONS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.